Proteasome dysfunction in aged human α-synuclein transgenic mice
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
A deficit in proteasome function in Parkinson's disease has been speculated. We characterized the ubiquitin–proteasome system in three regions of brain from transgenic and nontransgenic littermates. Mice expressing a doubly mutated form of human α-synuclein had significant impairments whereas mice expressing the wild-type gene had lesser changes compared to nontransgenic littermates. Significant abnormalities in line hm2α-SYN-39 included declines in 20S-mediated proteolytic activity, the level of the 19S proteasome subunits Rpt1 and Rpn2, and the level of soluble total high MW ubiquitin cross-reacting proteins. Line hwα-SYN-5 had significant, but restricted proteasome abnormalities. The severity of impairment was proportional to the substantia nigra dopaminergic neuronal loss previously identified. There were significant correlations between the level of Rpn2 with the level of Rpt1, the activity of the 20S proteasome, and the level of soluble high MW ubiquitin cross-reacting proteins. These abnormalities in symptomatic line hm2α-SYN-39 mice are consistent with abnormalities identified in tissue from patients with Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024 · cited 1×
“A role for UPS dysfunction is also speculated in PD due to mutations in two genes (parkin and ubiquitin carboxy-terminal hydrolase L1) associated with familial PD (fPD) that are linked to proteasome function (Shimura et al., 2000; Leroy et al., 1998).”
BackgroundShimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., & Selkoe, D. J. (2001) · Science · doi:10.1126/science.1060627 · Cited by 1,053
Proteasomal function is impaired in substantia nigra in Parkinson’s disease
McNaught, K. S. P., & Jenner, P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01701-8 · Cited by 653 · cited 1×
“…19S and 20S proteasome; Alpha synuclein Introduction Abnormalities in the ubiquitin–proteasome system (UPS) based on postmortem tissue studies have been associated with cases thought to represent idiopathic Parkinson’s disease (iPD) (McNaught and Jenner, 2001; McNaught et al., 2002a,b, 2003).”
BackgroundAltered proteasomal function in sporadic Parkinson’s disease
St. P. McNaught, K., Belizaire, R., Isacson, O., Jenner, P., & Olanow, C. W. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8050 · Cited by 573
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease
McNaught, K. S. P., Perl, D. P., Brownell, A., & Olanow, C. W. (2004) · Annals of Neurology · doi:10.1002/ana.20186 · Cited by 548
Clearance of α-Synuclein Oligomeric Intermediates via the Lysosomal Degradation Pathway
Lee, H.-J., Khoshaghideh, F., Patel, S., & Lee, S.-J. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3809-03.2004 · Cited by 445
Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions
Hasegawa, M., Fujiwara, H., Nonaka, T., Wakabayashi, K., Takahashi, H., Lee, V. M.-Y., Trojanowski, J. Q., Mann, D., & Iwatsubo, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208046200 · Cited by 428
Tofaris, G. K., Layfield, R., & Spillantini, M. G. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)03115-5 · Cited by 363
Decreased levels of proteasome activity and proteasome expression in aging spinal cord
Keller, J. N., Huang, F. F., & Markesbery, W. R. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00067-1 · Cited by 297
Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice
Richfield, E. K., Thiruchelvam, M. J., Cory-Slechta, D. A., Wuertzer, C., Gainetdinov, R. R., Caron, M. G., Di Monte, D. A., & Federoff, H. J. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7882 · Cited by 285
Self-citation
Cited by
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Parkinson’s disease: animal models and dopaminergic cell vulnerability
Blesa, J., & Przedborski, S. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00155 · Cited by 480
The pathogenesis of cell death in Parkinson's disease
Jenner, P., & Olanow, C. W. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s24 · Cited by 446
α-Synuclein and neuronal cell death
Cookson, M. R. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-9 · Cited by 418
Ebrahimi-Fakhari, D., Cantuti-Castelvetri, I., Fan, Z., Rockenstein, E., Masliah, E., Hyman, B. T., McLean, P. J., & Unni, V. K. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1560-11.2011 · Cited by 377
Metadata
- Authors
- Chen, L., Thiruchelvam, M. J., Madura, K., & Richfield, E. K.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2006-07
- Volume
- 23
- Issue
- 1
- Pages
- 120-126
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2002502410
- Cited by
- 88
- References
- 11
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proteasome dysfunction in aged human α-synuclein transgenic mice. https://app.cochat.ai/papers/10.1016/j.nbd.2006.02.004
- The paper
- Chen, L., Thiruchelvam, M. J., Madura, K., & Richfield, E. K. (2006). Proteasome dysfunction in aged human α-synuclein transgenic mice. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2006.02.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.